

5th European Conference on Schizophrenia Research: bridging gaps—improving outcomes

24–26 September 2015, Berlin, Germany

Guest Editors:

**Wolfgang Gaebel · Wolfgang Wölwer · Viktoria Toeller
(Düsseldorf, Germany)**

European Scientific Association on Schizophrenia and other Psychoses
(ESAS)

Head Office

c/o Department of Psychiatry and Psychotherapy

Heinrich-Heine-University Duesseldorf

LVR Klinikum Duesseldorf

Bergische Landstrasse 2

40629 Duesseldorf, Germany

Phone: + 49 (0)211/922-2770

Fax: + 49 (0)211/922-2780

E-Mail: info@esasnet.eu

www.esasnet.eu



Organization

European Scientific Association on Schizophrenia and other Psychoses (ESAS)

President: W. Gaebel, Düsseldorf, Germany

In cooperation with

World Psychiatric Association and its Schizophrenia Section
European Psychiatric Association and its Schizophrenia Section
German Association for Psychiatry and Psychotherapy
Competence Network on Schizophrenia (CNS)/PsychoseNetz e.V. (Local Organizer)

Scientific Secretariat

W. Gaebel, Düsseldorf, Germany
W. Wölwer, Düsseldorf, Germany
V. Toeller, Düsseldorf, Germany

Scientific Programme Committee

George Awad, Toronto, Canada
Dinesh Bhugra, London, United Kingdom
Gerd Buchkremer, Tübingen, Germany
George Christodoulou, Athens, Greece
Peter Falkai, Munich, Germany
Wolfgang Gaebel, Düsseldorf, Germany
Silvana Galderisi, Naples, Italy

Wagner F. Gattaz, Sao Paulo, Brazil
Birte Glenthjo, Copenhagen, Denmark
Philippe Gorwood, Paris, France
Heinz Häfner, Mannheim, Germany
Cyril Höschl, Prague, Czech Republic
Joachim Klosterkötter, Cologne, Germany
Valery Krasnov, Moscow, Russia
Shôn Lewis, Manchester, United Kingdom
Jan Libiger, Hradec Králové, Czech Republic
Wolfgang Maier, Bonn, Germany
Mario Maj, Naples, Italy
Stephen Marder, Los Angeles, USA
Patrick McGorry, Melbourne, Australia
Andreas Meyer-Lindenberg, Mannheim, Germany
Hans-Jürgen Möller, Munich, Germany
Merete Nordentoft, Copenhagen, Denmark
Sir Michael Owen, Cardiff, United Kingdom
Victor Peralta, Navarra, Spain
Wulf Rössler, Zurich, Switzerland
Pedro Ruiz, Huston, USA
Bernard Sabbe, Antwerpen, Belgium
Norman Sartorius, Geneva, Switzerland
Frank Schneider, Aachen, Germany
Werner Strik, Bern, Switzerland
Wolfgang Wölwer, Düsseldorf, Germany

Congress President

W. Gaebel, Düsseldorf, Germany

The supplement was not sponsored by outside commercial interests. The costs for publication were fully covered by delegates' payments of registration fees.

Plenary Lectures

- PL-01 An integrated sociodevelopmental-cognitive model of schizophrenia
- PL-02 Perspectives of drug development for the treatment of schizophrenia in clinical trials and the clinic
- PL-03 Predictors and mechanisms of conversion to psychosis

Pro-Con-Debates

- D-01 Early medication discontinuation in first-episode schizophrenia—beneficial or risky?
- D-02 Should “schizophrenia” be renamed?

Symposia

- S-01 Interventions in people at high risk of psychosis: new results of intervention trials
- S-02 Models for understanding negative symptoms
- S-03 What happens in adolescence? Developmental aspects in developing psychosis
- S-04 Structural and functional effects of ECT in patients with schizophrenic and affective psychoses
- S-05 Novel technologies to investigate motor behavior in psychiatric disorders
- S-06 The single symptom approach: understanding and treating auditory verbal hallucinations and formal thought disorders
- S-07 Patient perspectives, quality of life and affective symptoms in the early treated course of psychotic disorders
- S-08 Multimodal imaging of the psychosis high-risk state
- S-09 New findings about what dopamine does in the prefrontal cortex: relevance to schizophrenia
- S-10 Autoimmune encephalitis and mild encephalitis—from epidemiology to clinic
- S-11 Social cognition in schizophrenia and beyond
- S-12 Predictive coding and sensory disturbances in schizophrenia: from mice to men
- S-13 Neuroimaging approaches to understanding negative symptoms
- S-14 Modulating neural plasticity for the treatment of schizophrenia
- S-15 Depressive episodes in the course of schizophrenia-spectrum disorders: clinical challenges, therapeutic strategies
- S-16 Clozapine: the art of prescribing
- S-17 Bridging animal–human NMDAR models of schizophrenia through EEG biomarkers in behaving rodents and humans
- S-18 Impact of negative symptoms on schizophrenia functional outcome
- S-19 Verbal and nonverbal communication deficits in schizophrenia
- S-20 Psychological treatments for posttraumatic stress disorder in psychosis: feasibility, safety and efficacy
- S-21 Neuroinflammation and infection in schizophrenia
- S-22 Symptom dimensions and their clinical implication in schizophrenia
- S-23 Lifespan development of schizophrenia and how the treatments improve it
- S-24 Improving outcomes: factors influencing help seeking behavior, duration of untreated psychosis and treatment outcome in immigrants and ethnic minorities with first episode psychosis

- S-25 Detecting psychosis proneness: schizotypy and clinical high risk
- S-26 Disturbed connectivity in schizophrenia: from dysfunctional white matter tracts to molecular findings
- S-27 The role of psychotherapy in the treatment of schizophrenia
- S-28 Assessment of negative symptoms: challenges and recent developments
- S-29 Paranoia as a symptom dimension in schizophrenia
- S-30 Predicting Psychosis—Methodological concepts and first findings of the ‘Personalised Prognostic Tools for Early Psychosis Management’ (PRONIA) project
- S-31 Avolition and asociality: bridging gaps between animal and human research
- S-32 Social cognition in schizophrenia—new task developments and establishing paradigms
- S-33 Schizophrenia as neurodevelopmental disorder and effects of antipsychotic treatment: new insights from animal models
- S-34 Gaps in knowledge around and implementation of early intervention for psychosis: setting an agenda for the future
- S-35 Clinical and biological impact of exercise interventions in schizophrenia
- S-36 Cancelled
- S-37 The neurobiology of language related symptoms in schizophrenia
- S-38 Computational approaches to schizophrenia
- S-39 Epidemiological and clinical aspects of psychosis risk syndromes and psychotic experiences in children, adolescents and adults
- S-40 Current state and perspectives of policies for schizophrenia care
- S-41 Evidence for brain stimulation methods in schizophrenia
- S-42 Dopamine and learning dysfunction in schizophrenia
- S-43 Cycloid psychoses and chronic schizophrenia: clinical profiles and the role of CNVs
- S-44 Bridging the gap between treatment engagement and treatment outcomes
- S-45 Abnormalities of motor function in neuropsychiatric disorders: a transdiagnostic approach

Oral Presentations

- O-01 Early Detection and Intervention
- O-02 Neuroimaging
- O-03 Drug Treatment
- O-04 Comorbidity
- O-05 Alternative Treatment Approaches
- O-06 Psychosocial Treatment
- O-07 Neuropsychology

Poster Presentations

- P-01 Epidemiology and Health Services Research
- P-02 Diagnosis and Classification
- P-03 Drug and Somatic Treatment I
- P-04 Neuropsychology I
- P-05 Genes and Gene-Environment Interaction
- P-06 Neurobiology and Animal Models
- P-07 Outcome
- P-08 Psychosocial Factors and Interventions
- P-09 Neuropsychology II
- P-10 Neuroimaging I
- P-11 Early Stages of Schizophrenia

- P-12 Comorbidity
- P-13 Drug and Somatic Treatment II
- P-14 Psychophysiology
- P-15 Neuroimaging II

Author Index

S-05-002**Video-based quantification of body movement indicates negative symptoms: a replication**

Z. Kupper (University Hospital of Psychiatry, University of Bern, Bern, Switzerland; F. Ramseyer, M. Drozynski, H. Hoffmann, W. Tschacher)

Objective: In schizophrenia, abnormalities in nonverbal behaviors have always been considered as highly relevant. However, due to methodological limitations, nonverbal behavior was rarely quantified objectively. Recent methodological advances now allow a quantification of body movement from ordinary video recordings. We showed that patients' objectively measured amount of movement in social role-play interactions was closely associated with their symptom profiles (Kupper, Ramseyer, Hoffmann, & Tschacher, Schizophrenia Research 2010). In the present study, a replication of these results in the context of semi-standardized PANSS (Positive and Negative Syndrome Scale) interviews was intended.

Methods: 17 patients with schizophrenia were analyzed during the initial 15-min sequence of a videotaped PANSS interview using Motion Energy Analysis (MEA). The amount of patients' movement was then correlated with their PANSS symptom scores.

Results: Sizeable and significant correlations between negative symptoms and reduced movements ($r = -.68, p < 0.01$) and reduced movement speed ($r = -.80, p < 0.001$) were found. Moreover, cognitive symptoms were related to reduced movement speed ($r = -.70, p < .01$).

Conclusion: Negative symptoms were reliably indicated by patients' nonverbal behavior in psychopathology interviews. Hence, the main result of our earlier study, examining patients' nonverbal behavior in role play tests, was replicated for the less structured interactions in psychopathological interviews. Results could encourage the use of MEA in a wide range of videotaped social interactions of patients with schizophrenia and other psychiatric disorders.

Policy of full disclosure: None.

S-05-003**Association between instrumental measurements of dyskinesia and schizotypy in subjects with auditory verbal hallucinations and healthy controls**

A. Willems (GGz Centraal Centers for Mental Health Care, Amersfoort, The Netherlands; I. Sommer, D. Tenback, J. Koning, P. van Harten)

Objective: Spontaneous dyskinesia is associated with non-affective psychosis but few studies have been done on its relation with sub-clinical psychotic experiences. The concept of psychosis as a continuous phenomenon suggests similar associations at the non-clinical end of the psychosis spectrum. We examined spontaneous dyskinesia and schizotypy in subjects without a psychiatric diagnosis who experience auditory verbal hallucinations (AVH), patients with a non-affective psychotic disorder, and healthy controls.

Methods: The current study was part of a larger study in subjects experiencing AVH with no diagnosis of a psychotic disorder. Subjects with AVH and healthy controls were recruited using a website with information about hearing voices (www.verkenuwgeest.nl). Mean force variability (FV) was taken as a proxy for upper extremity dyskinesia and was measured with a mechanical instrument. Dyskinesia was defined as a FV score higher than the 95th percentile of the control group. Schizotypal tendency was assessed by means of the Schizotypal Personality Questionnaire (SPQ).

Results: Participants with AVH, healthy controls and psychotic patients did not differ with regard to gender, age or total years of education. The

cut-off score for FV derived from the 95th percentile in the control group was 3.11. Based on this criterion, 1, 8 and 14 persons in the control-, AVH group and patients showed dyskinesia. Testing the AVH against the control group and patients revealed significant differences (Fisher's Exact Test 2-sided; $p = 0.028$ and $p = 0.037$ respectively). The correlation between FV and schizotypy measured with Pearson's r was .35 ($p = 0.021$) in the AVH and .31 ($p = 0.046$) in the control group.

Conclusion: Our findings of intermediate levels of dyskinesia in persons with AVH in comparison with healthy controls and patients with a psychotic disorder, and the relationship between mechanically measured dyskinesia and schizotypy in control and AVH group are in accordance with psychosis as a continuous phenomenon.

Policy of full disclosure: This study was part of a larger study on Auditory Verbal Hallucinations which was supported by a grant from the Dutch Science Organisation (Nederlandse Wetenschappelijke Organisatie NWO, nr 916.56.172).

S-05-004**Actigraphy movement patterns indicate psychopathological dimensions in schizophrenia**

S. Walther (University of Bern, Department of Psychiatry, Bern, Switzerland)

Objective: Schizophrenia spectrum disorders are frequently associated with various motor abnormalities, including hypokinesia. In addition, psychopathological signs may involve presentation with motor output. Wrist actigraphy has proven feasible for ambulatory monitoring of activity in schizophrenia. Here, we summarize the findings associated with psychopathological dimensions.

Methods: In a series of studies in schizophrenia spectrum disorders we recorded spontaneous motor behavior using wrist actigraphy. In addition, we assessed psychopathology with the PANSS and the Bern Psychopathology Scale.

Results: In two studies, reduced motor activity was associated with increased negative syndrome severity. In fact, in a longitudinal study, low activity levels predicted the outcome of negative symptoms within and between psychotic episodes. Among negative symptoms, anhedonia/avolition had strongest correlations with activity levels. When the temporal structure of movement patterns was analyzed, positive symptom severity and disorganization correlated with irregular movement patterns, whereas negative symptoms were not related to the stability of movement patterns. The Bern Psychopathology scale contains a global motor evaluation, which demonstrated excellent agreement with objective assessments of activity levels.

Conclusion: Hypokinesia may be easily and objectively assessed with wrist actigraphy in schizophrenia spectrum disorders. Hypokinesia correlates cross-sectionally and longitudinally with negative syndrome severity. Instead, instable movement patterns are associated with disorganization. Thus, actigraphy may inform on symptom dimensions in schizophrenia.

Policy of full disclosure: None.

S-06 The single symptom approach: understanding and treating auditory verbal hallucinations and formal thought disorders**S-06-001****Auditory hallucinations and ego-disturbances: imaging of dysfunctional brain networks**

J. Gallinat (Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Hamburg- Eppendorf, Hamburg, Germany)